A Phase II Trial of Perifosine Following Tyrosine Kinase Inhibitor (TKI) - Failure in Patients With Renal Cancer

Inclusion Criteria:

* Patients will be required to have clear cell renal cell carcinoma with less than 50% of any other histology (papillary or chromophobe or oncocytic). There must be histologic confirmation by the treating center of either the primary or a metastatic lesion
* Patients must have experienced disease progression by RECIST criteria while on sorafenib or sunitinib
* Patients must be off of sorafenib or sunitinib for \>= 2 weeks prior to initiation of perifosine and \<= 3 months prior to enrollment
* Patients may have had sorafenib or sunitinib in the adjuvant setting as long as they have experienced disease recurrence while on therapy
* Patients must have measurable disease that is not curable by standard radiation therapy or surgery
* Age \>= 18 years
* ECOG performance status 0 or 1
* \- Patients must have the ability to understand and willingness to sign a written informed consent document

Exclusion Criteria:

* History or clinical evidence of CNS disease, including primary brain tumor, seizures not controlled with standard medical therapy, any brain metastasis, or history of stroke
* Other than sorafenib or sunitinib, patients may have only had prior immunotherapy for stage IV disease
* Patients may have had prior sorafenib OR sunitinib and cannot have been treated with both TKIs
* Patients who have stopped sorafenib or sunitinib due to toxicity but have only progressed off therapy will not be allowed
* Patients may have had prior anti-angiogenic such as bevacizumab only if given in combination with either sorafenib or sunitinib
* Prior Thalidomide or IFNα are allowed for adjuvant therapy or stage IV disease
* Patients may not have had prior mTOR inhibitors (CCI-779, RAD001)